Numis disclosed Circassia Pharmaceuticals Plc (LON:CIR), hiking its price target to 150.00GBX earlier today
- Updated: September 26, 2016
Reporting a potential upside of 0.60%, Numis upped the price target of Circassia Pharmaceuticals Plc (LON:CIR) to 150.00GBX
On 07/11/2016, Cantor Fitzgerald released a statement about Circassia Pharmaceuticals Plc (LON:CIR) dropped the target price from 500.00GBX to 110.00GBX that suggested an upside of 0.08%.
Having a price of 93.88GBX, Circassia Pharmaceuticals Plc (LON:CIR) traded -2.06% lower on the day. With the last stock price down -47.49% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CIR has recorded a 50-day average of 94.95GBX and a two hundred day average of 181.40GBX. Trade Volume was down over the average, with 151,874 shares of CIR changing hands under the typical 420,067
Recent Performance Chart
Circassia Pharmaceuticals Plc has with a one year low of 81.05GBX and a one year high of 322.90GBX and has a market capitalization of 0 GBX.
A total of 3 brokerages have released a report on Circassia Pharmaceuticals Plc. Four brokerages rating the company a strong buy, two brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 255.00GBX.
General Company Details For Circassia Pharmaceuticals Plc (LON:CIR)
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.